期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

MGMT在替莫唑胺治疗难治性垂体腺瘤中作用的研究进展

Effect of MGMT temozolomide therapy in refractory pituitary adenomas
暂未订购
导出
摘要 垂体腺瘤占颅内肿瘤发病率的15％，发病率居颅内肿瘤的第2位，近年来发病率有增高的趋势。根据文献报道，通过系统的放射学检查和尸检，在17％～25％的普通人群中可以发现垂体腺瘤。大部分垂体腺瘤生长缓慢，局限性生长，但有30％～40％的垂体瘤呈侵袭性生长，对于此类肿瘤，无论采用经蝶入路手术，或经额下、翼点入路手术，均难以全部切除，且术后约有20％的病例发生肿瘤复发。
作者 代从新 郭恺 张波 姚勇
机构地区 中国医学科学院北京协和医学院北京协和医院神经外科 大连医科大学附属第一医院神经外科
出处 《神经疾病与精神卫生》 2013年第1期95-97,共3页 Journal of Neuroscience and Mental Health
关键词 综述文献 垂体腺瘤 难治性 MGMT 替莫唑胺 Reviews Refractory pituitary adenomas MGMT Temozolomide
分类号 R736.4 [医药卫生—肿瘤]
  • 相关文献

参考文献25

  • 1Melmed S. Mechanisms for pituitary tumorigenesis : the plastic pituitary[J]. J Clin Invest, 2003,112(11) :1 603-1 618.
  • 2Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pi- tuitary adenomas: a systematic review[J]. Cancer, 2004, 101 (3) :613-619.
  • 3Li-Ng M, Sharma M. Invasive pituitary adenoma[J]. J Clin Endocrinol Metab,2008,93(9):3 284-3 285.
  • 4Zada G, Woodmansee WW, Ramkissoon S, et al. Atypical pi- tuitary adenomas: incidence, clinical characteristics, and im- plications[J]. J Neurosurg,2011,114(2) :336-344.
  • 5代从新,蔡锋,刘小海,马四海,姚勇,王任直.难治性垂体腺瘤的治疗现状和展望[J].中华神经外科杂志,2012,28(4):425-427. 被引量：3
  • 6Marucci G. Treatment of pituitary neoplasms with temozolo- mide: Areview[J]. Cancer,2011,117(17) :4101-4102.
  • 7Meeormack AI, Wass JA, Grossman AB. Aggressive pituitary tumours: the role of temozolomide and the assessment of MG- MTstatus[J]. EurJ ClinInvest,2011,41(10):1 133-1 148.
  • 8Mceormack AI, Mcdonald KL, Gill AJ, et' al. Low 06- methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours [J]. Clin Endocrinol (Oxf) ,2009,71(2):226-233.
  • 9Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolo- mide regimens: antitumor activity, toxicity, and immunomod- ulatory effects[J]. Cancer,2010,116(12) :2 868-2 877.
  • 10Reardon DA, Rich JN, Friedman HS, et al. Recent advances in the treatment of malignant astrocytoma[J].J Clin Oncol, 2006,24(8) :1 253-1 265.

二级参考文献41

  • 1Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pit- uitary adenomas: a systematic review. Cancer, 2004, 101:613-619.
  • 2Vance ML. Treatment of patients with a pituitary adenoma: one clinician's experience. Neurosurg Focus ,2004,16 : El.
  • 3Li-Ng M, Sharma M. Invasive pituitary adenoma. J Clin Endocrinol Metab ,2008,93:3284-3285.
  • 4Zada G, Woodmansee WW, Ramkissoon S, et al. Atypical pit- uitary adenomas : incidence, clinical characteristics, and implications. J Neurosurg,2011,114 :336-344.
  • 5Aghi MK. Management of recurrent and refractory Cushing dise- ase. Nat Clin Pract Endocrinal Metab ,2008,4:560-568.
  • 6Wang RZ. [ Selection of treatment methods for pituitary aden- oma]. Zhonzhua Yi Xue Za Zhi.2006.86 : 1585-1588.
  • 7Buchfelder M. Treatment of pituitary tumors: surgery. Endocr- ine ,2005,28:67-75.
  • 8Laws EJ. Pituitary pseudocapsule. J Neurosurg, 2006,104 : 1-2 ; discussion 2-3.
  • 9Lee E J, Ahn JY, Noh T, et al. Tumor tissue identification in the pseudocapsule of pituitary adenoma : should the pseudocapsule be removed for total resection of pituitary adenoma? Neurosurgery, 2009,64 ( 3 Suppl) : 62 -69 ; discussion 69 -70 .
  • 10Freda PU, Andreadis CI, Khandji AG, et al. Long-term treat- ment of prolactin-secreting macroadenomas with pergolide. J Clin Endocfinol Metab ,2000,85:8-13.

共引文献2

神经疾病与精神卫生
2013年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部